RU2748576C2 - Пэгилированные биологически активные пептиды и их применение - Google Patents

Пэгилированные биологически активные пептиды и их применение Download PDF

Info

Publication number
RU2748576C2
RU2748576C2 RU2018140501A RU2018140501A RU2748576C2 RU 2748576 C2 RU2748576 C2 RU 2748576C2 RU 2018140501 A RU2018140501 A RU 2018140501A RU 2018140501 A RU2018140501 A RU 2018140501A RU 2748576 C2 RU2748576 C2 RU 2748576C2
Authority
RU
Russia
Prior art keywords
peg
xaa
ghrh
ala
salt
Prior art date
Application number
RU2018140501A
Other languages
English (en)
Russian (ru)
Other versions
RU2018140501A (ru
RU2018140501A3 (enExample
Inventor
Кришна Дж. ПЕРИ
Original Assignee
Гриффон Фармасьютикалз Интернешнл Са.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гриффон Фармасьютикалз Интернешнл Са. filed Critical Гриффон Фармасьютикалз Интернешнл Са.
Publication of RU2018140501A publication Critical patent/RU2018140501A/ru
Publication of RU2018140501A3 publication Critical patent/RU2018140501A3/ru
Application granted granted Critical
Publication of RU2748576C2 publication Critical patent/RU2748576C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
RU2018140501A 2016-04-19 2017-04-18 Пэгилированные биологически активные пептиды и их применение RU2748576C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324600P 2016-04-19 2016-04-19
US62/324,600 2016-04-19
PCT/CA2017/050475 WO2017181277A1 (en) 2016-04-19 2017-04-18 Pegylated bioactive peptides and uses thereof

Publications (3)

Publication Number Publication Date
RU2018140501A RU2018140501A (ru) 2020-05-19
RU2018140501A3 RU2018140501A3 (enExample) 2020-09-08
RU2748576C2 true RU2748576C2 (ru) 2021-05-27

Family

ID=60039750

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018140501A RU2748576C2 (ru) 2016-04-19 2017-04-18 Пэгилированные биологически активные пептиды и их применение

Country Status (18)

Country Link
US (2) US10918730B2 (enExample)
EP (1) EP3445778B1 (enExample)
JP (1) JP7134093B2 (enExample)
KR (1) KR102520348B1 (enExample)
CN (1) CN109153712B (enExample)
AU (1) AU2017254754B2 (enExample)
BR (1) BR112018070929A2 (enExample)
CA (1) CA3021231A1 (enExample)
DK (1) DK3445778T3 (enExample)
ES (1) ES2824781T3 (enExample)
HU (1) HUE052802T2 (enExample)
IL (1) IL262356B2 (enExample)
MX (1) MX2018012716A (enExample)
PL (1) PL3445778T3 (enExample)
PT (1) PT3445778T (enExample)
RU (1) RU2748576C2 (enExample)
SG (1) SG11201808880PA (enExample)
WO (1) WO2017181277A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205498A1 (en) 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease
CN116194344B (zh) 2020-10-09 2026-06-30 奥托立夫开发公司 安全气囊装置
CN114195881B (zh) * 2021-12-16 2022-09-16 浙江湃肽生物股份有限公司 一种制备醋酸舍莫瑞林的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027897A1 (en) * 1997-12-03 1999-06-10 Applied Research Systems Ars Holding N.V. Site-specific preparation of polyethylene glycol-grf conjugates
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659693A (en) 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4914189A (en) 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
DE3726324A1 (de) 1987-08-07 1989-02-16 Hoechst Ag Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
NZ238748A (en) 1990-06-29 1993-09-27 Hoffmann La Roche Growth hormone releasing factor (grf) analogues
US5847006A (en) 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
DK0828758T3 (da) 1995-05-26 2002-01-07 Theratechnologies Inc Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
KR20020047096A (ko) 1999-07-26 2002-06-21 크로커 사무엘 에스 초활성 돼지 성장 호르몬 분비 호르몬 유사체
US7256258B2 (en) 2000-10-05 2007-08-14 Ares Trading S.A. Regioselective liquid phase pegylation
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
US8293708B2 (en) * 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
BRPI0915142A8 (pt) 2008-06-12 2018-01-02 Syntaxin Ltd Polipeptídeos, ácido nucleico e usos dos mesmos
US20110288011A1 (en) 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
BR112013027150A2 (pt) * 2011-04-21 2017-06-06 Theratechnologies Inc thera
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9079974B2 (en) 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
CN104946659A (zh) * 2015-03-27 2015-09-30 杭州北斗生物技术有限公司 重组人生长激素的制备方法及其peg化修饰物的制备方法
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027897A1 (en) * 1997-12-03 1999-06-10 Applied Research Systems Ars Holding N.V. Site-specific preparation of polyethylene glycol-grf conjugates
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ESPOSITO P. et al. PEGYLATION OF GROWTH HORMONE-RELEASING HORMONE (GRF) ANALOGUES, ADVANCED DRUG DELIVERY REV, 2003, v. 55, n. 10, p.1279 - 1291. *
FRANKEL A.E. et al. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng., 2000, v.13, n.8, p.575-581. *
MUNAFO A. et al. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects, EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, v. 153, n. 2, p.249 - 256. *
MUNAFO A. et al. Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects, EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, v. 153, n. 2, p.249 - 256. ESPOSITO P. et al. PEGYLATION OF GROWTH HORMONE-RELEASING HORMONE (GRF) ANALOGUES, ADVANCED DRUG DELIVERY REV, 2003, v. 55, n. 10, p.1279 - 1291. *
PAKULA A.A. et al. Genetic analysis of protein stability and function. Anna. Rev. Genet. 1989, v.23, p.289-310. *
PAKULA A.A. et al. Genetic analysis of protein stability and function. Anna. Rev. Genet. 1989, v.23, p.289-310. FRANKEL A.E. et al. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng., 2000, v.13, n.8, p.575-581. TOKURIKI N. et al. Stability effects of mutations and protein evolvability, Curr. Opin. Struct. Biol., 2009, v.19, n.5, p.596-604. TREETHARNMATHUROT B. et al. Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin, International Journal of Pharmaceutics, 2008, v. 357, p. 252-259. *
TOKURIKI N. et al. Stability effects of mutations and protein evolvability, Curr. Opin. Struct. Biol., 2009, v.19, n.5, p.596-604. *
TREETHARNMATHUROT B. et al. Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin, International Journal of Pharmaceutics, 2008, v. 357, p. 252-259. *

Also Published As

Publication number Publication date
EP3445778A4 (en) 2019-05-01
US20170296628A1 (en) 2017-10-19
PL3445778T3 (pl) 2021-02-22
RU2018140501A (ru) 2020-05-19
US10918730B2 (en) 2021-02-16
AU2017254754B2 (en) 2021-02-04
IL262356A (en) 2018-11-29
US20190209699A1 (en) 2019-07-11
KR102520348B1 (ko) 2023-04-10
US9988428B2 (en) 2018-06-05
EP3445778B1 (en) 2020-07-15
ES2824781T3 (es) 2021-05-13
PT3445778T (pt) 2020-10-15
DK3445778T3 (da) 2020-10-12
EP3445778A1 (en) 2019-02-27
BR112018070929A2 (pt) 2019-02-26
JP7134093B2 (ja) 2022-09-09
IL262356B2 (en) 2023-06-01
CA3021231A1 (en) 2017-10-26
JP2019516675A (ja) 2019-06-20
RU2018140501A3 (enExample) 2020-09-08
CN109153712B (zh) 2022-09-16
SG11201808880PA (en) 2018-11-29
WO2017181277A1 (en) 2017-10-26
KR20180135016A (ko) 2018-12-19
HUE052802T2 (hu) 2021-05-28
CN109153712A (zh) 2019-01-04
AU2017254754A1 (en) 2018-11-01
MX2018012716A (es) 2019-02-11

Similar Documents

Publication Publication Date Title
US12187773B2 (en) Modified GIP peptide analogues
EP2124974B1 (en) Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
US11572399B2 (en) Long-acting GIP peptide analogues
US20210107953A1 (en) Active polypeptide compound
KR102117216B1 (ko) 강력한 작용제 효과를 지닌 신규한 ｇｈ-ｒｈ 유사체
KR20250140094A (ko) Gip/glp1/gcg 삼중-수용체 효능제 및 그의 용도
US9988428B2 (en) Pegylated bioactive peptides and uses thereof
RU2540012C2 (ru) Мотилин-подобное пептидное соединение, обладающее приданной ему трансмукозальной абсорбционной способностью
US8361964B2 (en) Growth hormone releasing factor (GRF) analogs and uses thereof
AU2018214650B2 (en) Compounds, compositions and uses thereof for improvement of bone disorders
RU2817673C2 (ru) Модифицированные аналоги GIP пептида